Intersect ENT (XENT) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intersect ENT Reports Third Quarter 2014 Results
November 5, 2014 4:01 PM ESTMENLO PARK, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter of 2014.
Recent Accomplishments
Achieved Q3 revenue of $9.1 million, an increase of 113% over the third quarter of 2013. Â Realized Q3 gross margin of 72% versus 66% in the third quarter of 2013. Â Commenced enrollment in September of the PROGRESS study, a prospective, randomized, blinded, multi-center trial to assess the safety and efficacy of the... More